InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: ladavis23 post# 34475

Tuesday, 09/16/2014 12:33:11 PM

Tuesday, September 16, 2014 12:33:11 PM

Post# of 426537
1) First clue comes quickly, in today's statement: Specifically 8-k language: "However, FDA concluded that in its view the totality of scientific data and information, including its reevaluation and improved understanding of the relevant scientific knowledge since the ANCHOR trial began, does not support use of decreases in triglycerides as a validated surrogate for cardiovascular risk reduction in the proposed patient population." Particularly the "including" part of the statement, which - although it appears to be simply a summary of the FDA's decision - points strongly in the direction of the company feeling it can make a strong case against the FDA's reasoning. Notice also, the inclusion of calling out the nature of the failed drugs as fenofibrates and nicotinic acid. Sounds like someone is getting their ducks in a row to me - either for further appeals/discussions with FDA relative to sNDA, or for 1st Amendment purposes.

2) Your very artfully veiled aspersion that I may have engaged in the folly of past advocacy efforts on behalf of AMRN, via letters, emails, etc. is completely wrong - I have engaged in none of those efforts. (Although I do very much applaud other investors who have taken time to shake as many governmental/regulatory/media trees as they can.)

3) Also, cut it with the claims that I have very little knowledge about the "plumbing of WS." My original comments had nothing to do with WS activities. Plumbing is for toilets.

You are reaching in all the wrong directions. So please also cut the "with all due respect," too. Pretty much everyone sees through that stuff.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News